The chickenpox rash clears up within a couple of weeks, but the virus that caused it never leaves. Varicella zoster virus, or VZV, retreats into nerve cells after the initial infection and stays there for the rest of your life. This permanent residency is what makes shingles possible decades later, and it is one of the traits that distinguishes VZV from the viruses behind common colds or the flu.
What Happens During the Initial Infection
When VZV first enters your body, usually through the respiratory tract, it multiplies and eventually reaches the skin, producing the familiar itchy, blistering rash. Your immune system fights back, and within about one to three weeks the blisters crust over and heal. Fever, fatigue, and itching subside. To most people, that looks and feels like the end of the story. In children, the illness is usually mild. Adults who catch it for the first time, however, face a much rougher course. Primary VZV infection in adults causes more than ten to twenty times the complications and serious outcomes seen in healthy children, with pneumonia being the most common serious consequence.1PubMed Central. Primary Varicella Pneumonia in an Adult With Robust Immune Status: A Case Report
But whether the initial illness is mild or severe, the virus is doing something in the background that your immune system cannot fully stop. While it is busy triggering skin blisters and activating your defenses, VZV is also traveling along nerve fibers toward clusters of nerve cells called ganglia, where it will set up a quiet, long-term residence.
How the Virus Hides in Your Nerve Cells
After the chickenpox rash resolves, VZV becomes latent in ganglia along virtually the entire length of your nervous system. It settles into cranial nerve ganglia near the brain, dorsal root ganglia along the spine, and autonomic ganglia that help regulate involuntary body functions.2PubMed Central. The neurobiology of varicella zoster virus infection During latency, the virus is not actively replicating and is not producing new virus particles. No obvious damage occurs to the neurons housing it.3Nature Reviews Disease Primers. Varicella zoster virus infection The virus essentially goes to sleep inside the cell, maintaining just enough of its genetic material to survive without triggering the immune alarm.
Detecting this dormant virus in human nerve tissue has been tricky for researchers. VZV cannot be grown from human ganglia in the lab the way many other viruses can. Its presence during latency was confirmed only through molecular techniques that detect viral DNA rather than live virus.2PubMed Central. The neurobiology of varicella zoster virus infection This is part of what makes VZV so sneaky: it hides in a form that is essentially invisible to the body’s surveillance system, producing no viral proteins that would alert immune cells to its presence.
VZV is not the only herpesvirus that pulls this trick. The family of human herpesviruses all share the ability to establish latency and potentially reactivate later. VZV has evolved an especially wide repertoire of strategies to dodge and manipulate your immune defenses, which helps explain how it maintains this lifelong relationship with its host.4PubMed Central. Manipulation of the Innate Immune Response by Varicella Zoster Virus
When the Virus Wakes Up Again
For many people, VZV stays dormant forever and never causes another problem. But in a significant minority, the virus reactivates, typically decades after the original chickenpox infection. The result is herpes zoster, better known as shingles. Unlike chickenpox, which produces a widespread rash across the body, shingles usually appears as a painful band or strip of blisters on one side of the torso or face, following the path of the nerve where the virus was hiding.
Reactivation happens when VZV-specific immune surveillance weakens. This decline is most common in older adults and in people whose immune systems are compromised by illness or medication.5PubMed Central. Varicella Zoster Virus in the Nervous System Once the virus reawakens, it begins replicating inside the nerve cell and travels back down the nerve fiber toward the skin. Researchers have calculated that during a shingles episode, the virus moves along a human sciatic nerve at a speed of roughly 5.5 millimeters per hour.6PubMed Central. Calculation of the anterograde velocity of varicella-zoster virions in a human sciatic nerve during shingles That is extremely slow in absolute terms, but it is fast enough to reach the skin and cause damage within days.
When the virus arrives at the skin’s surface, it triggers inflammation, blistering, and cell death in the tissues served by that nerve. The most dreaded complication is postherpetic neuralgia, a persistent burning or stabbing pain that lingers in the affected area long after the rash has healed.3Nature Reviews Disease Primers. Varicella zoster virus infection For some people, this pain lasts months or even years and can be debilitating.
Shingles Without a Rash
One of the more unsettling aspects of VZV reactivation is that it does not always produce visible blisters. A condition known as zoster sine herpete, literally “zoster without rash,” involves radicular pain along a nerve path with no accompanying skin lesions.7PubMed. Varicella-zoster virus reactivation without rash This is rare, but it poses a real diagnostic puzzle. Without the telltale blistering strip, neither the patient nor the doctor may suspect VZV reactivation. The pain can be mistaken for a pinched nerve, a herniated disc, or another musculoskeletal problem.
Confirming zoster sine herpete requires detecting VZV DNA directly, often through a skin scraping from the affected area even when no blisters are present. In one documented case, a patient experienced persistent neuropathic pain that was initially treated as presumed shingles, but a definitive diagnosis was only reached after a DNA test on an intact skin scraping came back positive for VZV.8PubMed Central. Zoster Sine Herpete: Confirmatory Diagnosis Using Varicella-Zoster Virus DNA Polymerase Chain Reaction Analysis of Intact Skin Scrapings The condition highlights how the dormant virus can cause trouble in ways that are not immediately recognizable, even to experienced clinicians.
Who Faces the Greatest Risks
The consequences of carrying VZV for life are not equally distributed. Several groups face higher stakes, either from the initial infection or from reactivation later.
- Older adults: The immune system’s ability to keep VZV suppressed naturally wanes with age. Roughly one in three people who had chickenpox will develop shingles at some point, and the risk climbs steeply after age 50. Postherpetic neuralgia is also more common and more severe in older individuals.
- Pregnant women: Chickenpox during pregnancy is associated with serious risks for both mother and baby. VZV pneumonia in pregnant women can be life-threatening, and infection during the first or second trimester raises the risk of congenital varicella syndrome by an estimated 0.5 to 1.5 percent above the baseline risk for major birth defects.9PubMed. Chickenpox in pregnancy: revisited Neonatal varicella, when a newborn catches it around the time of delivery, also carries serious risks.10PubMed Central. Varicella-zoster virus (chickenpox) infection in pregnancy
- Cancer patients: People undergoing cancer treatment are at particularly high risk for severe VZV complications, including disseminated infections where the virus spreads beyond the skin to internal organs. Impaired immune function from chemotherapy or the cancer itself allows both initial infections and reactivations to become far more dangerous.11PubMed Central. Herpes Simplex Virus and Varicella Zoster Virus Infections in Cancer Patients
- Transplant recipients: People who have received organ or stem cell transplants take immunosuppressive drugs to prevent rejection, which also weakens the immune system’s grip on latent VZV.
For anyone in these groups, the fact that VZV stays in the body is not just an interesting biological detail. It is a practical concern that shapes medical decisions around vaccination, antiviral prophylaxis, and monitoring.
Vaccination Against Chickenpox and Shingles
The chickenpox vaccine, introduced in the mid-1990s, uses a weakened live strain of VZV. It dramatically reduces the chance of infection in the first place. In Taiwan, after a universal vaccination program was implemented, varicella incidence dropped from about 4.7 per 1,000 person-years to 0.8 per 1,000 person-years over a decade. Among roughly 930,000 vaccinated children tracked in the study, only about 2.8 percent experienced a breakthrough case, and just a tiny fraction of those required hospitalization.12PubMed Central. Epidemiology of Breakthrough Varicella after the Implementation of a Universal Varicella Vaccination Program in Taiwan, 2004-2014
An important nuance: the vaccine virus itself is a live (though weakened) form of VZV, which means it can also establish latency in nerve ganglia, just as the wild virus does. Vaccinated people can develop shingles later in life, though the risk appears to be lower than for people who had natural chickenpox. This is why shingles vaccination exists as a separate product aimed at older adults.
The newer recombinant shingles vaccine (Shingrix) takes a different approach. Rather than using live virus, it contains a single VZV protein combined with an immune-boosting ingredient. Studies have shown it significantly increases the body’s cellular immune response against VZV, even in people with weakened immune systems such as stem cell transplant recipients.13PubMed Central. Cellular Immune Response after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Because it does not contain live virus, Shingrix can be given to immunocompromised people who could not safely receive the older live shingles vaccine. It is recommended for adults age 50 and older, regardless of whether they remember having chickenpox.
The Economic and Personal Cost of a Lifelong Virus
The fact that VZV never leaves the body creates a rolling public health burden that extends well beyond the childhood rash. Modeling for an unvaccinated U.S. population projected roughly 1.1 million shingles cases, 114,000 cases of postherpetic neuralgia, and 43,000 ocular complications annually, amounting to about $2.4 billion in direct medical costs and lost productivity each year.14PubMed. Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition Those figures reflect the reality that shingles is not just a nuisance. It sends people to the hospital, keeps them out of work, and imposes lasting pain that erodes quality of life.
The economic burden of shingles has been increasing over time, driven in part by aging populations. Medical management and prescription drugs represent the largest share of direct costs, while the indirect costs, such as missed work, fall most heavily on people who develop shingles during their working years.15PubMed Central. Evaluation of the economic burden of Herpes Zoster (HZ) infection Research from Italy found that shingles patients reported a mean worst pain score of 5.7 out of 10 at diagnosis, and patients who developed postherpetic neuralgia were still reporting similarly severe pain three months later.16PubMed Central. The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy The human toll, measured in pain and lost function, easily outstrips what the dollar figures suggest.
Why Chickenpox Was Once Confused With Smallpox
For centuries, chickenpox and smallpox were assumed to be variations of the same disease. The two infections produce superficially similar rashes with fluid-filled blisters, and before modern virology there was no way to distinguish the underlying viruses. It was not until 1767 that the English physician William Heberden published a detailed clinical description of chickenpox as a distinct illness, finally separating it from the far deadlier smallpox.17PubMed Central. Poxes great and small: The stories behind their names
The connection between chickenpox and shingles took even longer to work out. Although doctors had noticed that shingles sometimes appeared in people who had previously had chickenpox, the idea that the same virus could cause both diseases was not established until the twentieth century. And the full understanding of viral latency, the mechanism by which VZV hides in nerve ganglia for decades between the two illnesses, came only with molecular biology tools developed in the latter half of the 1900s. It is a reminder that the “chickenpox goes away” assumption held by most people was also the medical consensus for a very long time. The realization that the virus persists changed how medicine thinks about childhood infections, vaccination policy, and the long-term care of aging populations.
Can You Ever Get Rid of the Virus Entirely?
As of now, there is no treatment that eliminates latent VZV from the body. Antiviral drugs like acyclovir and valacyclovir are effective at shortening and reducing the severity of both chickenpox and shingles when given early, but they work by interfering with viral replication. They cannot reach a virus that is sitting dormant inside a neuron, not actively copying itself. Once VZV has established latency, it is beyond the reach of current antivirals.
Research into latency-reversing strategies exists in the broader herpesvirus field, with most attention focused on herpes simplex virus and HIV’s latent reservoir. The idea is to flush the virus out of hiding so the immune system or antiviral drugs can finish it off. For VZV specifically, this line of research is still in early stages, and no clinical approach to clearing latent VZV from human ganglia has been developed. For the foreseeable future, anyone who has had chickenpox or received the live vaccine carries VZV in their nerve cells permanently.
That permanence is why vaccination strategy has two layers. The childhood vaccine aims to prevent the virus from ever taking up residence in the first place, reducing the pool of latently infected people over time. The adult shingles vaccine accepts that the virus is already there and focuses on boosting the immune system’s ability to keep it in check. Both layers are necessary because even decades of population-wide childhood vaccination will not eliminate shingles in the generations who were infected before the vaccine existed. The dual strategy reflects the stubborn biological reality that VZV, once acquired, is a lifelong companion.